Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review

Rocha-Filho, César Ramos; Ramalho, Gabriel Sodré; Martins, Johnny Wallef Leite; Lucchetta, Rosa Camila; Pinto, Ana Carolina Pereira Nunes; Rocha, Aline Pereira da; Trevisani, Giulia Fernandes Moça; Reis, Felipe Sebastião de Assis; Ferla, Laura Jantsch; Mastroianni, Patrícia de Carvalho; Corrêa, Luci; Saconato, Humberto; Trevisani, Virgínia Fernandes Moça

doi:10.1016/j.jped.2023.05.003

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ramos et al 38 analyzed the costs of treating hospitalized pediatric patients with RSV and Parainfluenza Virus Type 3 (PIV3) in upper-middle-income countries through a systematic review through July 2022. Cost analyses were reported for Colombia, China, Malaysia, and Mexico.…”

Section: Discussionmentioning

confidence: 99%

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Moreno,

Bardach,

Palermo

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This Systematic Review assesses the economic impact of Respiratory Syncytial Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource utilization and associated costs. We searched online databases from January 2012 to November 2022 to identify eligible publications. We identified 12 publications that reported direct costs, indirect costs, and resources associated with RSV and its complications. The primary direct medical resources reported were medical services, diagnostics tests and procedures, and length of stay (LOS). Direct total costs per patient ranged widely from $563 to $19,076. Direct costs are, on average, 98% higher than indirect costs. Brazil reported a higher total cost per patient than Colombia, El Salvador, México, Panamá, and Puerto Rico, while for indirect costs per patient, El Salvador and Panamá had higher costs than Brazil, Colombia, and Mexico. The mean LOS in the general ward due to RSV was 6.9 days (range 4 to 20 days) and the mean Intensive Care Unit LOS was 9.1 days (range 4 to 16 days). In many countries of the LAC region, RSV represents a considerable economic burden on health systems, but significant evidence gaps were identified in the region. More rigorous health economic studies are essential to better understand this burden and to promote effective healthcare through an informed decision-making process. Vaccination against RSV plays a critical role in mitigating this burden and should be a priority in public health strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Moreno,

Bardach,

Palermo

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

Confronting the challenge: a regional perspective by the Latin American pediatric infectious diseases society (SLIPE) expert group on respiratory syncytial virus—tackling the burden of disease and implementing preventive solutions

Debbag,

Ávila-Agüero,

Brea

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children around the world. The post-pandemic era has resulted in a notable increase in reported cases of RSV infections, co-circulation of other respiratory viruses, shifts in epidemiology, altered respiratory season timing, and increased healthcare demand. Low- and middle-income countries are responsible for the highest burden of RSV disease, contributing significantly to health expenses during respiratory seasons and RSV-associated mortality in children. Until recently, supportive measures were the only intervention to treat or prevent RSV-infection, since preventive strategies like palivizumab are limited for high-risk populations. Advances in new available strategies, such as long-acting monoclonal antibodies during the neonatal period and vaccination of pregnant women, are now a reality. As the Regional Expert Group of the Latin American Pediatric Infectious Diseases Society (SLIPE), we sought to evaluate the burden of RSV infection in Latin America and the Caribbean (LAC) region, analyze current strategies to prevent RSV infection in children, and provide recommendations for implementing new strategies for preventing RSV infection in children in LAC region.

show abstract

Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review

Cited by 2 publications

References 24 publications

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Confronting the challenge: a regional perspective by the Latin American pediatric infectious diseases society (SLIPE) expert group on respiratory syncytial virus—tackling the burden of disease and implementing preventive solutions

Contact Info

Product

Resources

About